Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier P Gisbert

Showing results (481-490 of 568) with videos related to

Pageof 57
Sort By:
Therapeutic Advances in Gastroenterology|June 29, 2026
Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCUInmaculada Alonso-Abreu, Laura Ramos, Alejandro Hernandez-Camba, et al.
Antibiotics (Basel, Switzerland)|August 27, 2021
The Role of Statins on <i>Helicobacter pylori</i> Eradication: Results from the European Registry on the Management of <i>H. pylori</i> (Hp-EuReg)María Caldas, Ángeles Pérez-Aisa, Bojan Tepes, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 13, 2019
Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of PatientsAdrian G McNicholl, Dmitry S Bordin, Alfredo Lucendo, et al.
Alimentary Pharmacology & Therapeutics|May 3, 2025
Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCUMaría José Casanova, Cristina Rubín de Célix, Sabino Riestra, et al.
Medicina (Kaunas, Lithuania)|September 27, 2025
Acute Pancreatitis in Inflammatory Bowel Disease: Results from the European Pandora StudyMaria Cristina Conti Bellocchi, Martina Cattani Mottes, Andreas Blesl, et al.
The American Journal of Gastroenterology|November 20, 2023
Effectiveness of Helicobacter pylori Treatments According to Antibiotic ResistanceLuis Bujanda, Olga P Nyssen, June Ramos, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 3, 2021
Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involvedLuis G Guijarro, David Cano-Martínez, M Val Toledo-Lobo, et al.
Helicobacter|July 14, 2020
Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg)Olga P Nyssen, Angeles Perez-Aisa, Luis Rodrigo, et al.
Therapeutic Advances in Gastroenterology|May 14, 2025
Natural history, immunological and genetic characteristics of preclinical inflammatory bowel disease (EARLY): study protocol for a prospective cohort studyIago Rodríguez-Lago, Urko M Marigorta, Beatriz Mateos, et al.
Journal of Crohn'S & Colitis|December 5, 2021
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA RegistryMargalida Calafat, Míriam Mañosa, Elena Ricart, et al.
Pageof 57

Showing results (481-490 of 568) with videos related to

Sort By:
Pageof 57
Therapeutic Advances in Gastroenterology|June 29, 2026
Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCUInmaculada Alonso-Abreu, Laura Ramos, Alejandro Hernandez-Camba, et al.
Antibiotics (Basel, Switzerland)|August 27, 2021
The Role of Statins on <i>Helicobacter pylori</i> Eradication: Results from the European Registry on the Management of <i>H. pylori</i> (Hp-EuReg)María Caldas, Ángeles Pérez-Aisa, Bojan Tepes, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 13, 2019
Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of PatientsAdrian G McNicholl, Dmitry S Bordin, Alfredo Lucendo, et al.
Alimentary Pharmacology & Therapeutics|May 3, 2025
Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCUMaría José Casanova, Cristina Rubín de Célix, Sabino Riestra, et al.
Medicina (Kaunas, Lithuania)|September 27, 2025
Acute Pancreatitis in Inflammatory Bowel Disease: Results from the European Pandora StudyMaria Cristina Conti Bellocchi, Martina Cattani Mottes, Andreas Blesl, et al.
The American Journal of Gastroenterology|November 20, 2023
Effectiveness of Helicobacter pylori Treatments According to Antibiotic ResistanceLuis Bujanda, Olga P Nyssen, June Ramos, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 3, 2021
Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involvedLuis G Guijarro, David Cano-Martínez, M Val Toledo-Lobo, et al.
Helicobacter|July 14, 2020
Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg)Olga P Nyssen, Angeles Perez-Aisa, Luis Rodrigo, et al.
Therapeutic Advances in Gastroenterology|May 14, 2025
Natural history, immunological and genetic characteristics of preclinical inflammatory bowel disease (EARLY): study protocol for a prospective cohort studyIago Rodríguez-Lago, Urko M Marigorta, Beatriz Mateos, et al.
Journal of Crohn'S & Colitis|December 5, 2021
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA RegistryMargalida Calafat, Míriam Mañosa, Elena Ricart, et al.
Pageof 57